Retifanlimab (Zynyz) is a humanized IgG4 kappa monoclonal antibody produced in Chinese hamster ovary cells. It is formulated as solution for intravenous route of administration. Zynyz is indicated for ...

Retifanlimab is under clinical development by Incyte and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma.

Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors In this report, we present a ...

Bytnar et al, Incidence Rates of Soft Tissue Sarcoma among U.S. Military Servicemen: Comparison with the Rates in the General U.S. Population, Cancer (2024). DOI: 10.1002/cncr.35607 ...

with the goal of assessing whether they differed in the occurrence of soft tissue sarcoma, providing clues for future research on related factors. Due to small numbers of active servicewomen in ...